Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 11, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00924-21
Keywords
Acinetobacter baumanii; Gram-negative resistance; novel antibiotics; nosocomial infections; durlobactam; Gram-negative bacteria; antibiotic resistance; antimicrobial agents; beta-lactamases; beta-lactams; sulbactam-durlobactam
Categories
Ask authors/readers for more resources
A successful case of treating XDR Acinetobacter baumannii pneumonia and septic shock with a novel antibiotic obtained via expanded access protocol was reported, suggesting that focused research and drug development efforts can mitigate the poor outcomes associated with these infections.
Extremely drug-resistant (XDR) Acinetobacter baumannii causes challenging nosocomial infections. We report the case of a patient with XDR A. baumannii pneumonia and septic shock successfully treated with cefiderocol and a novel antibiotic obtained via expanded access protocol. With focused research and drug development efforts, the poor outcomes associated with these infections may be mitigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
